<DOC>
	<DOCNO>NCT01775644</DOCNO>
	<brief_summary>This observastonal multicenter study evaluate difference progression-free survival define subgroup patient metastatic colorectal cancer receive Avastin ( bevacizumab ) . Further , safety efficacy daily routine assess . Data collect 5 year .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Patients With Metastatic Colorectal Cancer ( Koralle )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age &gt; = 18 year Patients metastatic colorectal cancer investigator decide give firstline , fluoropyrimidinebased combination therapy Avastin® accord Summary Product Characteristics ( SmPC ) Written sign inform consent prior onset documentation Contraindications Avastin® accord Summary Products Characteristics ( SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>